Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Pyxis Oncology Inc’s stock clocked out at $1.62, up 6.58% from its previous closing price of $1.52. In other words, the price has increased by $6.58 from its previous closing price. On the day, 0.91 million shares were traded. PYXS stock price reached its highest trading level at $1.64 during the session, while it also had its lowest trading level at $1.51.
Ratios:
To gain a deeper understanding of PYXS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.33 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
On November 08, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $13.
On August 08, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $10.Stifel initiated its Buy rating on August 08, 2024, with a $10 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 26 ’24 when Connealy Pamela Ann bought 88,850 shares for $1.96 per share. The transaction valued at 174,364 led to the insider holds 1,199,143 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 96334432 and an Enterprise Value of -27943520. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.36 while its Price-to-Book (P/B) ratio in mrq is 0.63. Its current Enterprise Value per Revenue stands at -1.731 whereas that against EBITDA is 0.456.
Stock Price History:
Over the past 52 weeks, PYXS has reached a high of $6.85, while it has fallen to a 52-week low of $1.51. The 50-Day Moving Average of the stock is -48.23%, while the 200-Day Moving Average is calculated to be -57.40%.
Shares Statistics:
It appears that PYXS traded 1.20M shares on average per day over the past three months and 1427180 shares per day over the past ten days. A total of 59.45M shares are outstanding, with a floating share count of 41.13M. Insiders hold about 30.83% of the company’s shares, while institutions hold 51.89% stake in the company. Shares short for PYXS as of 1732838400 were 6083882 with a Short Ratio of 5.06, compared to 1730332800 on 5855879. Therefore, it implies a Short% of Shares Outstanding of 6083882 and a Short% of Float of 12.43.
Earnings Estimates
The market rating of Pyxis Oncology Inc (PYXS) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.29 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$1.0 and -$1.38 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$1.21, with 7.0 analysts recommending between -$0.77 and -$1.46.